Skip to main content
. 2020 Dec 4;36(1):45–62. doi: 10.3904/kjim.2020.319

Figure 1.

Figure 1

Recommended algorithm for the treatment of primary myelofibrosis. IPSS, International Prognostic Scoring System; DIPSS, Dynamic International Prognostic Scoring System. aRuxolitinib for low or intermediate-1 risk patients is approved by the Ministry of Food and Drug Safety but not currently covered by National Health Insurance system of Korea, bRuxolitinib treatment before transplantation to alleviate symptoms and splenomegaly can be considered.